Generon BioMed Holding

Evive Biotech (formerly Generon BioMed Holding) is a clinical-stage biotechnology company dedicated to developing innovative biological therapies for oncology, inflammatory, and metabolic diseases. As a subsidiary of Yifan Pharmaceutical, the company operates a global platform with research and manufacturing facilities in China, Singapore, and the United States. Its lead product, Ryzneuta (efbemalenograstim alfa), is a novel long-acting G-CSF that has received regulatory approval from the FDA and NMPA for the treatment of chemotherapy-induced neutropenia. Evive Biotech utilizes its proprietary ITab (Immunotherapy Antibody) and Di-Kine platforms to advance a diverse pipeline, including F-652, a first-in-class IL-22 fusion protein currently in Phase 2 trials for conditions such as Graft-versus-Host Disease and acute pancreatitis.